Rein Therapeutics (RNTX) investor relations material

Opening remarks and agenda

• The meeting was called to order by the CEO, who welcomed participants to the virtual format and introduced the board and management team.

• Rules of conduct and procedures for participation and voting were outlined, with confirmation that all stockholders received notice and proxy materials.

Corporate governance

• A quorum was established with 74.47% of shares represented, allowing business to proceed.

• The agenda included the election of two Class III directors, approval of increased authorized shares, appointment of an independent audit firm, and a non-binding advisory vote on executive compensation.

Overview of voting outcomes

• Both director nominees were elected to serve until the 2029 annual meeting.

• The proposal to increase authorized shares was approved.

• CBIZ was appointed as the independent audit firm.

• Executive compensation was approved on a non-binding advisory basis.

• Final vote results will be disclosed in a Form 8-K filing within four business days.